Tandem Diabetes Care, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Tandem Diabetes Care, Inc. (TNDM) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $15.64 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-06
- Tandem Diabetes Care, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $15.64M, a 39.08% decline year-over-year.
- Tandem Diabetes Care, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $15.17M, a 40.31% decline year-over-year.
- Tandem Diabetes Care, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-12-31 was $19.77M, a 29.78% decline year-over-year.
- Tandem Diabetes Care, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $20.99M, a 20.72% decline year-over-year.
- Tandem Diabetes Care, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $91.85M, a 9.21% decline from fiscal 2024.
- Tandem Diabetes Care, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $101.17M, a 13.77% increase from fiscal 2023.
- Tandem Diabetes Care, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $88.93M, a 4.52% increase from fiscal 2022.
- Tandem Diabetes Care, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $85.08M, a 39.26% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $15.64M 10-Q · filed 2026-08-06 | $30.81M 10-Q · filed 2026-08-06 | $50.58M derived: sum of 3 quarters · filed 2026-08-06 | $71.57M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $15.17M 10-Q · filed 2026-05-07 | $34.94M derived: sum of 2 quarters · filed 2026-05-07 | $55.93M derived: sum of 3 quarters · filed 2026-05-07 | $81.61M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $19.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $40.76M derived: sum of 2 quarters · filed 2026-02-19 | $66.44M derived: sum of 3 quarters · filed 2026-08-06 | $91.85M 10-K · filed 2026-02-19 |
| 2025-09-30 | $20.99M 10-Q · filed 2025-11-06 | $46.67M derived: sum of 2 quarters · filed 2026-08-06 | $72.08M 10-Q · filed 2025-11-06 | $100.23M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $25.68M 10-Q · filed 2026-08-06 | $51.09M 10-Q · filed 2026-08-06 | $79.24M derived: sum of 3 quarters · filed 2026-08-06 | $105.72M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $25.41M 10-Q · filed 2026-05-07 | $53.56M derived: sum of 2 quarters · filed 2026-05-07 | $80.04M derived: sum of 3 quarters · filed 2026-05-07 | $104.99M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $28.15M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $54.63M derived: sum of 2 quarters · filed 2026-02-19 | $79.58M derived: sum of 3 quarters · filed 2026-02-19 | $101.17M 10-K · filed 2026-02-19 |
| 2024-09-30 | $26.48M 10-Q · filed 2025-11-06 | $51.43M derived: sum of 2 quarters · filed 2025-11-06 | $73.02M 10-Q · filed 2025-11-06 | $96.46M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | $24.95M 10-Q · filed 2025-08-06 | $46.54M 10-Q · filed 2025-08-06 | $69.98M derived: sum of 3 quarters · filed 2026-02-19 | $90.56M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | $21.59M 10-Q · filed 2025-04-30 | $45.03M derived: sum of 2 quarters · filed 2026-02-19 | $65.61M derived: sum of 3 quarters · filed 2026-02-19 | $89.02M derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | $23.44M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $44.02M derived: sum of 2 quarters · filed 2026-02-19 | $67.43M derived: sum of 3 quarters · filed 2026-02-19 | $88.93M 10-K · filed 2026-02-19 |
| 2023-09-30 | $20.58M 10-Q · filed 2024-11-06 | $43.99M derived: sum of 2 quarters · filed 2024-11-06 | $65.48M 10-Q · filed 2024-11-06 | $90.11M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | $23.41M 10-Q · filed 2024-08-01 | $44.91M 10-Q · filed 2024-08-01 | $69.54M derived: sum of 3 quarters · filed 2025-02-26 | $91.89M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | $21.50M 10-Q · filed 2024-05-02 | $46.13M derived: sum of 2 quarters · filed 2025-02-26 | $68.48M derived: sum of 3 quarters · filed 2025-02-26 | $88.64M derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | $24.63M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $46.99M derived: sum of 2 quarters · filed 2025-02-26 | $67.15M derived: sum of 3 quarters · filed 2025-02-26 | $85.08M 10-K · filed 2025-02-26 |
| 2022-09-30 | $22.36M 10-Q · filed 2023-11-01 | $42.52M derived: sum of 2 quarters · filed 2023-11-01 | $60.45M 10-Q · filed 2023-11-01 | $77.53M derived: sum of 4 quarters · filed 2024-02-21 |
| 2022-06-30 | $20.16M 10-Q · filed 2023-08-03 | $38.09M 10-Q · filed 2023-08-03 | $55.17M derived: sum of 3 quarters · filed 2024-02-21 | $71.05M derived: sum of 4 quarters · filed 2024-02-21 |
| 2022-03-31 | $17.93M 10-Q · filed 2023-05-03 | $35.02M derived: sum of 2 quarters · filed 2024-02-21 | $50.89M derived: sum of 3 quarters · filed 2024-02-21 | $66.01M derived: sum of 4 quarters · filed 2024-02-21 |
| 2021-12-31 | $17.09M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $32.96M derived: sum of 2 quarters · filed 2024-02-21 | $48.08M derived: sum of 3 quarters · filed 2024-02-21 | $61.09M 10-K · filed 2024-02-21 |
| 2021-09-30 | $15.87M 10-Q · filed 2022-11-02 | $30.99M derived: sum of 2 quarters · filed 2022-11-02 | $44.01M 10-Q · filed 2022-11-02 | $57.21M derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-06-30 | $15.12M 10-Q · filed 2022-08-03 | $28.13M 10-Q · filed 2022-08-03 | $41.34M derived: sum of 3 quarters · filed 2023-02-22 | $53.64M derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-03-31 | $13.01M 10-Q · filed 2022-05-04 | $26.22M derived: sum of 2 quarters · filed 2023-02-22 | $38.52M derived: sum of 3 quarters · filed 2023-02-22 | $54.93M derived: sum of 4 quarters · filed 2023-02-22 |
| 2020-12-31 | $13.20M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $25.50M derived: sum of 2 quarters · filed 2023-02-22 | $41.92M derived: sum of 3 quarters · filed 2023-02-22 | $57.73M 10-K · filed 2023-02-22 |
| 2020-09-30 | $12.30M 10-Q · filed 2021-11-03 | $28.71M derived: sum of 2 quarters · filed 2021-11-03 | $44.52M 10-Q · filed 2021-11-03 | $63.41M derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-06-30 | $16.41M 10-Q · filed 2021-08-04 | $32.22M 10-Q · filed 2021-08-04 | $51.10M derived: sum of 3 quarters · filed 2022-02-22 | $68.68M derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-03-31 | $15.81M 10-Q · filed 2021-05-05 | $34.69M derived: sum of 2 quarters · filed 2022-02-22 | $52.27M derived: sum of 3 quarters · filed 2022-02-22 | $64.68M derived: sum of 4 quarters · filed 2022-02-22 |
| 2019-12-31 | $18.88M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-22 | $36.46M derived: sum of 2 quarters · filed 2022-02-22 | $48.87M derived: sum of 3 quarters · filed 2022-02-22 | $58.62M 10-K · filed 2022-02-22 |
| 2019-09-30 | $17.57M 10-Q · filed 2020-11-05 | $29.99M derived: sum of 2 quarters · filed 2020-11-05 | $39.74M 10-Q · filed 2020-11-05 | $49.79M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-06-30 | $12.41M 10-Q · filed 2020-07-30 | $22.16M 10-Q · filed 2020-07-30 | $32.22M derived: sum of 3 quarters · filed 2021-02-24 | $42.21M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-03-31 | $9.75M 10-Q · filed 2020-04-30 | $19.80M derived: sum of 2 quarters · filed 2021-02-24 | $29.80M derived: sum of 3 quarters · filed 2021-02-24 | $32.62M derived: sum of 4 quarters · filed 2021-02-24 |
| 2018-12-31 | $10.05M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $20.05M derived: sum of 2 quarters · filed 2021-02-24 | $22.86M derived: sum of 3 quarters · filed 2021-02-24 | $24.00M 10-K · filed 2021-02-24 |
| 2018-09-30 | $10.00M 10-Q · filed 2019-11-04 | $12.81M derived: sum of 2 quarters · filed 2019-11-04 | $13.95M 10-Q · filed 2019-11-04 | |
| 2018-06-30 | $2.81M 10-Q · filed 2019-08-01 | $3.95M 10-Q · filed 2019-08-01 | ||
| 2018-03-31 | $1.13M 10-Q · filed 2019-04-30 | |||
| 2017-12-31 | $12.56M 10-K · filed 2020-02-24 | |||
| 2016-12-31 | $11.75M 10-K · filed 2019-02-26 | |||
| 2015-12-31 | $13.05M 10-K · filed 2018-03-01 | |||
| 2014-12-31 | $14.92M 10-K · filed 2017-03-08 | |||
| 2013-12-31 | $4.72M 10-K · filed 2016-02-24 | |||
| 2012-12-31 | $246.00K 10-K · filed 2015-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| PROCEPT BioRobotics Corp (PRCT) | United States | $1.001B | -11.77 |
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| Beta Bionics, Inc. (BBNX) | United States | $0.979B | -9.66 |
| SpyGlass Pharma, Inc. (SGP) | United States | $0.925B | |
| INTEGRA LIFESCIENCES HOLDINGS CORP (IART) | United States | $1.234B | -193.02 |
| SI-BONE, Inc. (SIBN) | United States | $0.830B | -49.82 |
| MIMEDX GROUP, INC. (MDXG) | United States | $0.687B | 89.92 |
| ANGIODYNAMICS INC (ANGO) | United States | $0.632B | -13.02 |
| ORTHOPEDIATRICS CORP (KIDS) | United States | $0.592B |